Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 14/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382710 | 0.82 | GSK3B (0.70) | GSK3BMAPTALDH1A1HTT | |
| SCHEMBL6788481 | 0.82 | GSK3B (1.00) | GSK3BMEN1KMT2AMAPTKDM4E | |
| SCHEMBL18355585 | 0.81 | GSK3B (0.68) | GSK3BMEN1KMT2AMAPTKDM4E | |
| SCHEMBL13919889 | 0.80 | GSK3B (0.69) | GSK3BMEN1KMT2AMAPTKDM4E | |
| SCHEMBL23330896 | 0.77 | GSK3B (0.65) | GSK3BMEN1KMT2AMAPTKDM4E | |
| SCHEMBL8923637 | 0.77 | GSK3B (0.65) | GSK3BMEN1KMT2AMAPTKDM4E | |
| SCHEMBL7892619 | 0.77 | GSK3B (0.62) | GSK3BMEN1KMT2AMAPTKDM4E | |
| SCHEMBL15483703 | 0.76 | GSK3B (0.62) | GSK3BMEN1KMT2AMAPTKDM4E | |
| SCHEMBL23330785 | 0.74 | GSK3B (0.61) | GSK3BMEN1KMT2AMAPTKDM4E | |
| SCHEMBL899479 | 0.74 | GSK3B (0.61) | GSK3BMEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4627062-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| EP-4627058-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS | Nuwacell Biotechnologies Co., Ltd. (CN) | 2025-10-08 | — | — | EP | claimed |
| US-12188046-B2 | Culture medium, coating matrix and method for expanding midbrain dopaminergic progenitor cells | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2025-01-07 | — | — | US | claimed |
| US-20240352419-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED HEMATOPOIETIC LINEAGE CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-10-24 | — | — | US | claimed |
| US-20240327788-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-10-03 | — | — | US | claimed |
| US-20240327787-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-10-03 | — | — | US | claimed |
| US-20240316196-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-09-26 | — | — | US | claimed |
| US-20240200027-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-20 | — | — | US | claimed |
| WO-2024113358-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED NATURAL KILLER CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | claimed |
| WO-2024113352-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND DERIVED HEMATOPOIETIC LINEAGE CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | claimed |
| US-20150004255-A1 | PERITONEAL DIALYSIS FLUID COMPRISING A GSK-3 INHIBITOR | ZYTOPROTEC GMBH (AT) | 2015-01-01 | — | — | US | claimed |
| EP-2797596-A1 | PERITONEAL DIALYSIS FLUID COMPRISING A GSK-3 INHIBITOR | Zytoprotec GmbH (AT) | 2014-11-05 | — | — | EP | claimed |
| WO-2014083132-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | CELLECTIS SA (FR) | 2014-06-05 | — | — | WO | claimed |
| WO-2013098140-A1 | PERITONEAL DIALYSIS FLUID COMPRISING A GSK-3 INHIBITOR | ZYTOPROTEC GMBH (AT) | 2013-07-04 | — | — | WO | claimed |
| EP-2609918-A1 | Peritoneal dialysis fluid comprising a GSK-3 inhibitor | Zytoprotec GmbH (AT) | 2013-07-03 | — | — | EP | claimed |
| WO-2010108005-A2 | NOVEL NEURAL PROGENITORS FROM PLURIPOTENT STEM CELLS, METHODS OF PRODUCING SAME AND USE TO PRODUCE NEURAL CELLS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2010-09-23 | — | — | WO | claimed |
| US-20100166713-A1 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2010-07-01 | — | — | US | claimed |
| EP-2126045-A2 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008094597-A2 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-20060204980-A1 | Colorectal cancer therapies | MASSACHUSETTS, UNIVERSITY OF | 2006-09-14 | — | — | US | claimed |